The Association Between Loss of Medicare, Immunosuppressive Medication Use, and Kidney Transplant Outcomes
Affiliations
- PMID: 30838768
- PMCID: PMC6785998
- DOI: 10.1111/ajt.15293
Abstract
Kidney transplant recipients aged <65 years qualify for Medicare coverage, but coverage ends 3 years posttransplant. We determined the association between timing of Medicare loss and immunosuppressive medication fills and kidney allograft loss. Using data from the Scientific Registry of Transplant Recipients (SRTR), US Renal Data System, and Symphony pharmacy fill database, we analyzed 78 861 Medicare-covered, kidney-alone recipients aged <65 years, and assessed the timing of Medicare loss posttransplant: early (<3 years), on-time (at 3 years), or late (>3 years). Immunosuppressant use was measured as medication possession ratio (MPR). Allograft loss was assessed using SRTR data. MPR was lower for recipients with early or late Medicare loss compared with no coverage loss for all immunosuppressive medication types. For calcineurin inhibitors, early Medicare loss was associated with a 53% to 86% lower MPR. On-time Medicare loss was not associated with a lower MPR. When recipients were matched by age, posttransplant timing of Medicare loss, and donor risk, the hazard of allograft loss was 990% to 1630% higher after early Medicare loss, and 140% to 740% higher after late Medicare loss, with no difference in the hazard for on-time Medicare loss. Ensuring ongoing Medicare access before and after 3 years posttransplant could affect graft survival.
Keywords: Scientific Registry for Transplant Recipients (SRTR); clinical research/practice; insurance - public; kidney transplantation/nephrology.
Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
Conflict of interest statement
DISCLOSURE
The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation .
Similar articles
- Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current EraM Kadatz et al. J Am Soc Nephrol 31 (1), 218-228. PMID 31704739.Extending immunosuppressive drug coverage under Medicare from the current 36 months to the duration of transplant survival will result in better patient outcomes and cost …
- Refill-Based Medication Use Quality Measures in Kidney Transplant Recipients: Examination of Proportion of Days Covered and Medication Possession RatioBA Hofmeyer et al. J Manag Care Spec Pharm 24 (4), 367-372. PMID 29578851.MPR and PDC may be calculated from data available to pharmacies and health plans, and each was associated with 3-year late BPAR among patients who did not experience earl …
- Immunosuppressant Therapy Adherence and Graft Failure Among Pediatric Renal Transplant RecipientsMA Chisholm-Burns et al. Am J Transplant 9 (11), 2497-504. PMID 19681814.The study objective was to determine the association between immunosuppressant therapy (IST) adherence and graft failure among pediatric renal transplant recipients (RTRs …
- Calcineurin Inhibitor-Free Immunosuppression in Pediatric Renal Transplantation: A Viable Option?B Höcker et al. Paediatr Drugs 13 (1), 49-69. PMID 21162600. - ReviewThe introduction, in the mid-1980s, of calcineurin inhibitors - namely ciclosporin (cyclosporine) and later tacrolimus - has significantly improved short-term renal graft …
- Scientific Registry of Transplant Recipients: Collecting, Analyzing, and Reporting Data on Transplantation in the United StatesS Leppke et al. Transplant Rev (Orlando) 27 (2), 50-6. PMID 23481320. - ReviewFounded in 1987, the Scientific Registry of Transplant Recipients (SRTR) operates under a contract from the US government administered by the Health Resources and Service …
No hay comentarios:
Publicar un comentario